Posted on

Doseology Names CFO and Appoints New Board Member

Doseology Names CFO and Appoints New Board Member

Vernon, British Columbia, January 28, 2022 – Doseology Sciences Inc. (CSE: MOOD) (“Doseology” or the “Company”), a British Columbia-based diversified life sciences company developing mushroom-based health and wellness solutions, announces the appointment of Peter Geh as Chief Financial Officer, effective January 26, 2022, and the addition of Harbir Toor as Director and Independent Audit Chair, effective January 27, 2022.

Peter Geh is an experienced financial and accounting executive based in Kelowna, B.C. As a Chartered Professional Accountant with over fifteen years of corporate experience, he has guided several Canadian companies through growth stages in the healthtech, retail, and manufacturing industries.

Peter spent over ten years in public practice accounting working with entities in the public, private and not-for-profit sectors. As VP Finance of a Canadian tech company, Peter oversaw revenue growth of over 400 percent and staff growth of 75 percent during a two-year period.

“We’re very fortunate to have Peter join our team at this critical stage”, said Maryam Marissen, Doseology CEO. “His experience across several related industries in British Columbia, plus his ability to hone in on financial details while maintaining high-level perspective make him the ideal CFO for Doseology.”

On the appointment, Peter Geh remarked, “I am very excited about the opportunity to be a part of such an innovative, growing company like Doseology. To help guide us forward, I plan to leverage my specialties in strategic planning and execution, financial risk management, and shareholder value creation. I have a passion for helping companies of this size because I can take a very hands-on approach to financial management. I’m looking forward to working towards our goals with the Doseology team.”

Doseology Sciences Inc. has also named Harbir Toor, CPA, CA, as the Independent Audit Chair of the Board of Directors. Ms. Toor has 25 years of experience in strategic planning, risk management, governance, capital raises, and financial accounting. She began her career in audit at KPMG and most recently has held several senior executive positions in both private and publicly listed companies, including VP Finance and CFO in the biopharmaceutical and life sciences industries.

CEO Maryam Marissen commented, “Harbir is a tremendous asset for a diversified life sciences company such as ours. She has guided several other Canadian biotech and pharmaceutical companies in their financial and operational growth phases, and that relevant experience is truly invaluable.”

Ms. Marissen thanks Interim CFO Alex McAulay for his service to the Company. Doseology also announces that Mr. Gordon Jang has resigned as a Director and Independent Audit Chair of the Company, effective January 27, 2022. Mr. Jang will remain an advisor on Doseology’s financial matters and strategic decisions. Doseology wishes to thank Gordon for his valuable service and insight.

To support the Company’s mission and create profitable revenue streams in growing markets, Doseology is pursuing the cultivation of functional mushrooms, distribution of its medicinal mushroom nootropics products, and establishing clinical services. In November, the company applied for a Health Canada Dealer’s License, which upon approval will allow for psilocybin-related research and cultivation. 

To learn more about the Doseology management team and see recent company news, visit Doseology Investor Resources.

Maryam Marissen
Chief Executive Officer
Doseology Sciences Inc.
maryam@doseology.com

About Doseology Sciences Inc.
Doseology Sciences Inc. (CSE: MOOD) is a British Columbia-based diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on psychedelic and non-psychedelic compounds, Doseology will offer cutting edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health.

For further information contact:
Investor Relations: investor@doseology.com
Media Inquiries: media@doseology.com
Telephone: 236-349-0064
Website: www.doseology.com

Forward Looking Statements
This corporate update contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law.No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION IN THE UNITED STATES OR DISSEMINATION IN THE UNITED STATES

Posted on

Wesana Health Appoints Meghna A. Gaeta as Chief Marketing Officer

Wesana Health Appoints Meghna A. Gaeta as Chief Marketing Officer

CHICAGO and TORONTO, Jan. 25, 2022 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc.  (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, announced the appointment of Meghna A. Gaeta as Chief Marketing Officer. In this role, she will lead Wesana’s business marketing strategy. 

“Meghna has a proven track record of brand innovation and development strategies,” said Daniel Carcillo, Founder and CEO of Wesana. “As Wesana continues to expand its clinical network, Meghna’s expertise in practice growth and technology driven patient experiences will help to position Wesana as a premiere leader in the mental health care delivery space. We are thrilled to leverage her ability to bridge the gap that too often exists between patients and their care providers.”

Meghna brings more than 18 years of experience in healthcare, operations, and technology marketing for major, consumer-facing brands, such as Twitter and Walgreens. Meghna most recently led a boutique marketing consultancy, working closely with healthcare, retail & start-up tech clients. In this role, she championed innovative technology to increase access to health care and led and developed scaled ecommerce strategies and solutions. Previously, she served as the head of retail marketing, global business marketing & strategy for Twitter. She also played a pivotal role in establishing and growing a first-of-its-kind care model at Walgreens. There she supervised marketing efforts for 100 retail (pilot) clinics at Walgreens drugstores in over 10 major US markets.

“Wesana is at the forefront of transforming mental health services and drug development and doing it in a way that centers the patient experience from start to finish,” said Gaeta. “Having been a long-time advocate for improved mental health services, I see this new opportunity with Wesana as a space where we can take the lead in assuring patients that there is hope for them and that new therapies are coming soon that can help alleviate the pain they are suffering from. I’m looking forward to building on Wesana’s existing success and helping pave the path to effective and more accessible mental health care.”

Meghna holds a Master of Science Degree in Marketing Communications & eCommerce from IIT Stuart School of Business as well as a Bachelor’s Degree in Political Science from Bryn Mawr College. She is currently working toward a Master of Marriage and Family Therapy degree from The Chicago School of Professional Psychology.

Wesana also announces it has retained the services of North Equities, an investor communications and public relations company, to assist the Company to enhance its market awareness, and communications strategy. Under the terms of the North Equities engagement, which is for an initial six-month period, North Equities will be paid US$70,000 for the six-month term in form of 63,927 restricted stock units of the Company.

About Wesana Health

Wesana Health helps people transcend barriers in mental health and performance. We innovate in care development through our therapies and patent-pending protocols, and in care delivery through activating a new multidisciplinary, technology-supported clinical model. Learn more at www.wesanahealth.com.

Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to future partnerships, collaborative research and the focus of the Company’s business. Any such forward-looking statements may be identified by words such as “expects”, “anticipates”, “intends”, “contemplates”, “believes”, “projects”, “plans” and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance regarding the participation in, or success of, partnerships or collaborative research or that the Company will continue its business as described above. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Readers are encouraged to refer to the Listing Statement filed on Company’s profile on SEDAR at www.sedar.com for information as to the risks and other factors which may affect the Company’s business objectives and strategic plans.

For more information, please contact:
Media Contact:
Izzy Forman
VP, Communications
Email: media@wesanahealth.com

Nick Opich / Annie Graf
KCSA Strategic Communications
Email: Wesana@kcsa.com
Phone: 212-896-1206 / 786-390-2644

On behalf of the Board of Directors:
Daniel Carcillo, Chief Executive Officer
Phone: (773) 236-7972

Primary Logo

Source: Wesana Health

Released January 25, 2022

Posted on

XPhyto Announces Head of Sales, Europe

XPhyto Announces Head of Sales, Europe

Vancouver, Canada, and Uttenweiler, Germany (January 17, 2022) – XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce the appointment of Mr. Drahoslav Zdarek as the Company’s Head of Sales, Europe. Mr. Zdarek will focus on building out distribution, sales and marketing of the Company’s products, with high priority on the commercialization of Covid-ID Lab, the Company’s German CE Mark approved rapid RT-PCR test registered within the European Union as a commercial in vitro diagnostic (CE-IVD) test.

Mr. Zdarek has over 25 years of European pharmaceutical sales and marketing success. His previous positions include over 13 years of marketing and sales for Teva Pharmaceutical focusing on the European market, Head of Business Development at CC Pharma GmbH and Head of Sales at Cell Pharma GmbH, a subsidiary of Stada Arzneimittel AG. Mr. Zdarek is a licensed pharmacist and a certified trainer for the Covid-ID Lab test.

“Mr. Zdarek is an important addition to the Company, joining at the right time. With his technical experience as well as sales skills he will help expand our European distribution and sales networks,” said Prof. Dr. Thomas Beckert. “Today’s announcement is further to the recent appointments of Mr. Roland Spleiss as the Director of Business Development and Dr. Heinrich Jehle as the Head of Diagnostic Research. Strengthening the leadership is essential as the Company focuses resources on new product commercialization and sales growth of Covid-ID Lab and its novel oral biosensors.”

Covid-ID Lab is a rapid RT-PCR test for the qualitative detection of SARS-CoV-2 based on the reverse transcriptase polymerase chain reaction (RT-PCR) method. To perform the test, Covid-ID Lab requires only a 20-minute PCR run time without prior RNA extraction as part of the sample preparation. The RT-PCR sample process detects the SARS-CoV-2 virus on a test chip within 5 minutes, when SARS-CoV-2 is present, the result can be read visually immediately. The target customers are airports, cruise lines, pharmacies, medical clinics, and any industrial or education site that requires rapid, definitive results.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

Posted on

NeonMind Appoints Canadian Medical Leader In Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC To Its Specialty Clinics Advisory Board

NeonMind Appoints Canadian Medical Leader In Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC To Its Specialty Clinics Advisory Board

Dr. Bainbridge’s Expertise and Network Provides Safety Best-Practices for Administration of Intravenous Ketamine (IV-Ketamine) at NeonMind Clinics

Vancouver, B.C. – January 13, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company, announced today the appointment of Dr. Daniel Bainbridge, MD, FRCPC, past President of the Canadian Anesthesiologists Society, Professor from the Department of Anesthesia and Perioperative Medicine at the University of Western Ontario, and Anesthesia Consultant at London Health Sciences Centre, to its Specialty Clinics Advisory Board.

NeonMind’s medical services division is establishing specialty clinics to enhance access to interventional psychiatry treatments including intravenous ketamine treatment (“IV-ketamine”) which has shown promise as a rapid treatment for mood and anxiety disorders and has been included as a recommended treatment into Canadian guidelines by the Canadian Network for Mood and Anxiety Treatments1. Dr. Bainbridge will utilize his substantial experience to ensure NeonMind’s protocols, procedures, training, and practices of administering intravenous ketamine are best-in-class and practical from a safety perspective.  With over 20 years as a practicing anesthesiologist and his leadership role with the Canadian Anesthesiologists Society, Dr. Bainbridge has vast experience with ketamine and a large network of contacts for NeonMind to train and employ to assure patient safety.

“We are excited to welcome the Canadian leader in anesthesiology, Dr. Bainbridge, to our Specialty Clinics Advisory Board. At NeonMind, we are focused on enhancing access to interventional psychiatry to help address the mental health crisis, including IV-ketamine for mood and anxiety disorders. Safety is of utmost importance for NeonMind’s specialty clinics and, with Dr. Bainbridge’s involvement in building our programs, we can assure patients and healthcare providers they are receiving best-in-class care for their IV-ketamine administration. He will prove invaluable to enhancing access and wider adoption of NeonMind’s IV-ketamine treatment programs,” said Robert Tessarolo, President & CEO of NeonMind.

Dr. Bainbridge commented, “The evidence supports that IV-ketamine is safe and well tolerated at the therapeutic doses used to treat patients suffering from mood and anxiety disorders. The ketamine doses used are magnitudes lower than for procedural sedation, let alone general anesthesia. Ketamine administration requires specific procedures and expertise and can be safely provided in specialty clinics with the appropriately trained health care provider. My colleagues at NeonMind understand this with the aim of enhancing access to this transformational treatment for mood and anxiety disorders utilizing safe and effective care programs. I am excited to work with NeonMind in developing IV-ketamine administration practices and establishing a clinic network to enhance access to these treatment programs for patients in need.”

  1. Swainson, J., McGirr, A., Blier, P., Brietzke, E., Richard-Devantoy, S., Ravindron, N., Blier, J., McIntyre, R., Milev, R., Parikh, S., Schaffer, A., Taylor, V., Tourjman, V., van Ameringen, M., Yatham, L., Ravindran, A. and Lam, R., 2021. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder. The Canadian Journal of Psychiatry, 66(12), pp.1102-1102.

About NeonMind Biosciences Inc.

NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.

NeonMind and its strategic partners are building NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs. For more information on NeonMind, go to www.NeonMindBiosciences.com.


Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.

rob@neonmind.com

Tel: 416-750-3101

Investor Relations:

KCSA Strategic Communications

Scott Eckstein/Tim Regan

neonmind@kcsa.com

Tel: 212-896-1210

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

Posted on

Clearmind Medicine Strengthens Presence in North America with New Senior Appointments

Clearmind Medicine Strengthens Presence in North America with New Senior Appointments

Mr. Mark Haden appointed to VP Business Development and Mr. Gilad Babchuk as Head of Strategy and Communication

TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce senior appointments to its management team in North America.

Mr. Mark Haden, psychedelic medicine expert, has been appointed as the Company’s Vice President Business Development. Mr. Haden was promoted to this position after serving as one of the founding members of Clearmind’s scientific advisory.

Mr. Haden has spent his career working to advance the use of psychedelics in medicine.  Mark has substantial research experience, including a leadership role in the study of Psilocybin Research Investigating Medical Efficacy, which explores psilocybin as an adjunct in the treatment of substance use disorders, and has spent 10 years as the chairman and executive director of the Multidisciplinary Association for Psychedelic Studies in Canada, an organization he founded. He has also dedicated over 25 years to working directly with patients through the Vancouver Coastal Health Addiction Services. Mr. Haden currently serves as Director of Clinical Research at Psygen Industries, a manufacturer of pharmaceutical-grade psychedelic drug products for clinical research and therapeutic applications and is an Adjunct Professor at the University of British Columbia School of Population and Public Health.

Additionally, the Company wishes to announce that, Mr. Gilad Babchuk has been appointed as the Company’s Head of Strategy and Communication. Mr. Babchuk is a serial entrepreneur with 28 years of global experience in establishing, developing, and running organizations. He served as a strategic advisor to top-level managers in both the private and public sectors as well as to certain politicians at various governmental levels.  He was a founder and co-founder of over 15 social ventures, as well as a 4-time CEO. Gilad is an acclaimed speaker and is currently a consultant for multinational companies, working with senior CEOs, business leaders, and entrepreneurs worldwide.

Dr. Adi Zuloff-Shani, Ph.D., CEO of Clearmind, commented on the announcement, “As we continue to increase our footprint in North America, I am excited to welcome our newest team members. Since joining our scientific advisory board, Adjunct Prof. Haden’s contributions have been plentiful and we believe that as VP of Business Development, his expertise and connections will greatly improve the future progression of the company.”

“Mr. Babchuk has decades of experience in taking companies to their next stage with well-established strategies and tactics. I am confident that our new team members will support Clearmind in achieving its goals for the upcoming year and will facilitate efforts in North America,” Zuloff-Shani added.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of four patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND“, the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC pink under the symbol “CMNDF“.

For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

‍

Posted on

Universal Ibogaine Announces Change In Leadership

Universal Ibogaine Announces Change In Leadership

Calgary, AB – TheNewswire – January 10, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”) announces that Rami Batal has been replaced as Chief Executive Officer (“CEO”) of the Company and its subsidiaries.  For the present time, the Company has appointed Nick Karos as CEO, effective immediately.  Mr. Karos had recently been appointed as a Capital Markets consultant to the Company.

“We are grateful for Rami’s leadership and many contributions,” said Chief Ian Campbell, Chair of the UI Board of Directors.  “We wish Rami all the best.”

Mr. Karos is based in Los Angeles, USA, and is a seasoned financier.  His career includes senior roles with US investment banks, including serving at Piper Jaffray as head of Nasdaq Trading and Agency Services, and most recently as CEO of Private Trading Group, which has provided business development and capital raising services for several successful start-up ventures.

Mr. Karos said “I’m very excited to work with the talented partners at UI to move towards our goal of conducting clinical trials with Health Canada.  Universal Ibogaine’s goal is to transform the addiction treatment model using ibogaine as the cornerstone of our new addiction treatment protocol.  Addiction is a disease that affects society like none other, and we believe our ground-breaking protocol will give patients and families a better path towards long-term recovery.”

The Board of Directors will immediately begin an executive search process for selecting a new CEO.  Mr. Karos remains a short list candidate for the long term position.

About Universal Ibogaine Inc.

UI is a life sciences company, with a goal to develop a platform of addiction treatment clinics, which may eventually use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants.  

UI separately plans to clinically develop ibogaine, a natural plant substance, as an authorized addiction interruption medicine for the treatment of Opioid Use Disorder.  A Clinical Trial Application to Health Canada is being developed to undertake clinical trials in Canada, aimed at proving the safety and efficacy of the use of ibogaine for this purpose.  In the longer term, UI plans to introduce ibogaine into the addiction treatment protocols to be used in its’ future facilities.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

For further information:

Investor Relations: Dugan Selkirk – IR Manager

dugan.selkirk@universalibogaine.com

Media Contact: Cathy Fernandes – VP, Marketing & Communications cathy.fernandes@universalibogaine.com

Posted on

HAVN Life Announces Gary Leong’s Appointment to Board of Directors

HAVN Life Announces Gary Leong’s Appointment to Board of Directors

Mr. Leong brings with him a wealth of scientific and regulatory experience

Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company developing natural health products and innovative therapies to support brain health and enhance the capabilities of the mind, is pleased to announce the appointment of Mr. Gary Leong to its Board of Directors. Concurrently, Mr. Leong has stepped down as HAVN Life’s Chief Science Officer, shifting his focus to an advisory role within the organization.

Mr. Leong has been instrumental in the regulatory development and launch of HAVN Life’s Retail Division, formulating its portfolio of natural health products, launched in June of 2021. Gary Leong has more than thirty years of experience in the pharmaceutical and natural health product industries. Mr. Leong is currently acting as the Director of Quality and Compliance at the privately Licensed Cannabis Processor, Tricanna Industries Inc. He was the Chief Scientific Officer at Aphria Inc. in Leamington, ON from its inception in 2014 to 2019, where he established and oversaw the Quality Assurance, Quality Control, Regulatory Affairs and Research and Development functions. Prior to this, he served as the Chief Scientific Officer of Jamieson Laboratories in Windsor, ON for fourteen years. He has also managed the scientific and quality functions for Boehringer Ingelheim, Natural Factors Nutritional Products Ltd. and Nordion. Gary holds a B.Sc. in Chemistry and a M.B.A. in Quality Management and has served on the Board of Directors of several public companies and research societies, as well as an advisor to several Canadian government regulatory advisory committees.

“Mr. Leong has been a key member of the HAVN Life Sciences leadership team, especially with respect to launching HAVN Life’s Retail Division, and we are happy to welcome him to our Board of Directors where his scientific and regulatory experience will help us make strategic decisions for both our retail and psychedelic businesses as we move forward into further growth in 2022,” says HAVN Life’s Chairman of the Board, Mr. Vic Neufeld. “We thank him for his work and look forward to benefiting from his expertise as a Board Member,” he added.

HAVN Life Sciences closes out its inaugural year with an eye towards expanding its global retail presence in 2022.

###

On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.

HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.
Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.
Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.

Contact:

Investor Relations: ir@havnlife.com 604 687-7130
Media: savi@emergence-creative.com 647 896-8078

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

Posted on

Stephen Hurst Resigns from MindMed Board of Directors

Stephen Hurst Resigns from MindMed Board of Directors

NEW YORK, January 7, 2022 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-derived therapies, announces the resignation of Stephen Hurst from his role as a Director of the Company’s Board of Directors.

“On behalf of MindMed, the Board of Directors, and the Executive team, I thank Steve for his significant contributions and strategic guidance in bringing the Company to this stage of development,” said Robert Barrow, Chief Executive Officer and Director of MindMed. “The co-founders and early leadership of MindMed have been instrumental in establishing the Company and its strong foundation. Their work, vision, and the programs that they initiated will continue to serve as the basis for our execution of the Company’s mission. As we approach important milestones across our clinical development programs, we are extremely grateful for Steve’s effort to enable this progress.” 

Mr. Hurst added “MindMed is the culmination of my career and more than a decade of work to bring the benefits of psychedelic-inspired medicines to patients struggling with addiction and mental illness. With the recent appointment of two seasoned Directors and a brilliant Chief Executive Officer, I have the greatest confidence in the team’s ability to guide the Company through this next phase of continued progress toward the realization of our highest aspirations.”

About MindMed

MindMed is a clinical-stage biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address mental health and addiction. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed’s approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

For Media: media@mindmed.co

For Investors: ir@mindmed.co

Posted on

XPhyto Announces New Director of Business Development and Head of Diagnostic Research

XPhyto Announces New Director of Business Development and Head of Diagnostic Research

Vancouver, Canada, and Uttenweiler, Germany (January 10, 2022) – XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce two key appointments to continue its focus on research, development and commercialization of its biosensor and diagnostic products including for the detection of COVID-19.

Director of Business Development

Mr. Roland Spleiss has joined as the Director of Business Development. Mr. Spleiss is a seasoned commercial professional with over 25 years of experience in planning and building out effective salesforces, strategic realignment, production relocation, and project management, which makes him ideally suited to drive product sales.

In addition to extensive consulting roles, Mr. Spleiss held senior positions including Chief Financial Officer of Wörwag Pharma, a private German health and generic pharmaceutical company with over EUR 200 million in annual sales and 900 employees. He led the company’s strategic professionalization and internationalization of operations, optimization of supply chains and sales processes, and expansion into new European, Asian and Latin American healthcare markets.

Mr. Spleiss’ expertise in production and supply chain management, cost optimization, and sales force and distribution network creation will be invaluable to XPhyto’s commercial strategy and execution.

Head of Diagnostic Research

Dr. Heinrich Jehle has joined XPhyto as Head of Diagnostic Research. Dr. Jehle has over 20 years’ experience in the research and development of innovative medical screening tests and diagnostics. Previously, Dr. Jehle held senior roles in project management and research & development at leading European biotech and diagnostics companies.

More recently, Dr. Jehle co-founded 3a-diagnostics GmbH as managing director where he led the development of the first saliva activated “in-mouth” biosensor candidates to identify active pathogens in the saliva and built a portfolio of innovative diagnostics biosensor products. The enzyme-activated biosensors are developed for real-time, low-cost and easy-to-use oral screening applications for the rapid detection of infectious diseases including COVID-19 at home or at the point-of-care.

“Mr. Spleiss and Dr. Jehle are tremendous additions to the XPhyto team,” said Prof. Dr. Thomas Beckert. “Mr. Spleiss brings robust knowledge and experience in the development of product sales and economic optimization with a demonstratable track record of success. Dr. Jehle’s scientific expertise ensures the continued advancement and commercialization of innovative biosensor and diagnostic products, which is a key component of XPhyto’s short- and long-term success.”

XPhyto is pleased to have embarked on a recent process of rapid and transformative leadership change and organizational optimization.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

Posted on

Ketamine One Appoints Two New Members to Its Medical Advisory Board

Ketamine One Appoints Two New Members to Its Medical Advisory Board

Corey Hilmas, MD, PhD and Brigadier General (Ret.) Loree K. Sutton, MD Will Help Guide the Development of the Company’s Mental Health Platform 

Vancouver, British Columbia, January 5, 2022 / Globe Newswire / – KetamineOne Capital Limited  (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company  focused on consolidating medical clinics and becoming a North American leader in mental health  treatments, is pleased to announce that Corey Hilmas, MD, PhD has been appointed to the Company’s  Medical Advisory Board (“MAB”) and will be assuming the role of Interim Chair of the MAB.  Additionally, Brigadier General (Ret.) Loree K. Sutton, MD, has also been appointed to the MAB.  

Dr. Hilmas currently also serves as the Chief Regulatory Officer of the Company’s wholly owned  subsidiary, KGK Science Inc. He is a respected scientist, medical doctor, and former federal food regulator  in the United States (“US”). After having completed his medical degree and doctorate in toxicology,  working as a principal investigator for many years, and serving on behalf of the US government at the Food  and Drug Administration (“FDA”), Dr. Hilmas combines his unique medical and scientific skillset with  extensive U.S. regulatory training. He served as an New Dietary Ingredients notification reviewer and as a  branch chief within the Division of Dietary Supplement Programs at the FDA.  

In addition to working on enforcement matters related to supplement labeling, claims, good manufacturing  practices and fraud, he also served as an expert witness for the FDA and Department of Justice, resulting  in an FDA Award of Merit from former FDA Commissioner Margaret Hamburg. As a recognized  regulatory expert with intimate knowledge of the dietary supplement industry, Dr. Hilmas has made  significant contributions to building and shaping the regulatory landscape through drafting over 65  comments to multiple US federal and state agencies as well as global food health directorates on topics  ranging from soy to supplements and cannabidiol, to changing regulatory frameworks overseas.  

Dr. Sutton is a lifelong public servant, physician and retired brigadier general who was the Army’s highest ranking psychiatrist. She is the co-founder of Threshold GlobalWorks, LLC; the founding commissioner of  the NYC Department of Veterans’ Services; and, in her current position as CEO, Veteran Services USA,  has devoted over 35 years of service and leadership to the nation and New York. Sutton’s decorated military  career includes earning a Bronze Star for her actions in combat while deployed to Operation Desert Storm.  Selected as a White House Fellow, the nation’s premier leadership program, and honored by the National  War College as a distinguished graduate, she also commanded the Carl R. Darnall Army Medical Center at  Fort Hood, TX during the height of Operation Iraqi Freedom hostilities. 

Serving as the founding director, Defense Centers of Excellence for Psychological Health and Traumatic  Brain Injury, Loree pioneered integrative approaches for building resilience, enhancing recovery and  fostering community reintegration. Spanning decades of service in the public and private sectors, her  visionary leadership has yielded transformational change which continues to improve the lives of veterans,  families, caregivers and survivors.  

Additionally, Ketamine One has granted certain advisors an aggregate amount of 100,000 stock options to purchase up to 100,000 common shares of the Company, at a price of $0.30 per common share for a period of five years from the date of grant, pursuant to its stock option plan that was approved by shareholders on Feb. 21, 2021. Fifty per cent of the options vest six months from the date of grant, with the remaining fifty per cent of the options vesting 12 months after the date of the grant.  

ABOUT KETAMINE ONE 

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating  medical clinics and becoming a North American leader in mental health treatments. It is working to provide  the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently,  Ketamine One has a network of clinics across North America, with plans to further consolidate the highly  fragmented industry. KGK Science Inc. is the Company’s wholly owned contract research division, which  places it at the forefront of premium clinical research based on the subsidiary’s history and extensive  experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective  enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental  health therapy.  

On behalf of:  

KETAMINE ONE 

“Adam Deffett”  

Adam Deffett, Interim CEO  

For further information, please contact:  

Nick Kuzyk, Investor Relations  

Tel: 1-844-PHONE-K1 (1-844-746-6351)  

Email: IR@ketamine.one  

Web: www.ketamine.one 

Twitter: @KetamineOne  

Notice Regarding Forward-Looking Information: 

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward 

looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by 

such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.